Technical Analysis for VTVT - vTv Therapeutics Inc.

Grade Last Price % Change Price Change
D 14.03 2.29% 0.31
VTVT closed up 2.29 percent on Friday, November 1, 2024, on 11 percent of normal volume.
Earnings due: Nov 7
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Fell Below 20 DMA Bearish 2.29%
MACD Bearish Centerline Cross Bearish 2.29%
Calm After Storm Range Contraction 2.29%
Narrow Range Bar Range Contraction 2.29%
Gapped Down Weakness 2.29%

   Recent Intraday Alerts

Alert Time
20 DMA Resistance about 19 hours ago
Possible NR7 about 20 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
Gapped Up (Full) about 23 hours ago
Rose Above 20 DMA about 23 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

vTv Therapeutics Inc. Description

vTv Therapeutics Inc., a biopharmaceutical company, engages in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease includes azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. The company's type 2 diabetes drug candidates comprise TTP399, an orally administered, liver-selective glucokinase activator, which is in a Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor that has completed Phase I clinical trials. It is also developing HPP593, a functionally selective peroxisome proliferator-activated receptor delta agonist for the prevention of muscle weakness associated with prolonged mechanical ventilation and critical injury that has completed Phase Ib clinical trials; HPP737, an orally administered phosphodiesterase-4 inhibitor for the treatment of chronic obstructive pulmonary disease, psoriasis, and other inflammatory diseases, which has completed Phase Ib clinical trials; and HPP971, a Bach1 inhibitor, for the treatment of inflammation, autoimmune diseases, and diseases associated with oxidative stress, which is in Phase 1 clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to research, develop, and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Diabetes Autoimmune Disease Inflammation Alzheimer's Disease Parkinson's Disease Inflammatory Diseases Weakness Psoriasis Chronic Obstructive Pulmonary Disease Pulmonary Disease Organic Chemistry Pyridines Mechanical Ventilation Treatment Of Alzheimer's Disease Biotie Therapies Phosphodiesterase Tyrosine Kinase Inhibitors Buparlisib Oxidative Stress Treatment Of Inflammation

Is VTVT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.99
52 Week Low 7.425
Average Volume 20,290
200-Day Moving Average 17.78
50-Day Moving Average 14.49
20-Day Moving Average 14.22
10-Day Moving Average 14.50
Average True Range 0.87
RSI (14) 47.92
ADX 21.29
+DI 29.46
-DI 18.32
Chandelier Exit (Long, 3 ATRs) 14.63
Chandelier Exit (Short, 3 ATRs) 15.60
Upper Bollinger Bands 15.43
Lower Bollinger Band 13.01
Percent B (%b) 0.42
BandWidth 17.05
MACD Line -0.04
MACD Signal Line -0.02
MACD Histogram -0.0145
Fundamentals Value
Market Cap 28.58 Million
Num Shares 2.04 Million
EPS -10.80
Price-to-Earnings (P/E) Ratio -1.30
Price-to-Sales 2324.57
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.39
Resistance 3 (R3) 14.43 14.35 14.33
Resistance 2 (R2) 14.35 14.26 14.33 14.31
Resistance 1 (R1) 14.19 14.20 14.15 14.15 14.29
Pivot Point 14.11 14.11 14.09 14.09 14.11
Support 1 (S1) 13.95 14.02 13.91 13.91 13.77
Support 2 (S2) 13.87 13.96 13.85 13.75
Support 3 (S3) 13.71 13.87 13.73
Support 4 (S4) 13.67